// App-Quantinova.ai

OP011 : Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

Researchers

Presenter

  • L. Peyrin-Biroulet

Principal Investigators

  • B.G. Feagan

  • J. Mansfield

  • D.T. Rubin

  • U. Arulmani

  • R. Maciuca

  • H. Tyrrell

  • J. Thommes

  • S. Tole

Medical Centers

  • Universite de Lorraine, Vandoeuvre les Nancy, France

  • University of Western Ontario, London, ON, Canada

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • University of Chicago, Chicago, IL, United States

  • Genentech Inc., San Francisco, United States

  • Roche, Welwyn Garden City, United Kingdom

Locations

  • France

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Faecal calprotectin

Drug/Treatment

  • Etrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • NCT02100696

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved